• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

    4/23/25 10:59:03 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAR alert in real time by email
    6-K 1 pharmingreceivespositivere.htm 6-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 6-K



    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the Month of April 2025



    Commission File Number: 001-39822



    Pharming Group N.V.
    (Exact Name of Registrant as Specified in Its Charter)



    Darwinweg 24
    2333 CR Leiden
    The Netherlands
    (Address of principal executive offices)



    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐



    Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated April 23, 2025.






    EXHIBIT INDEX
    Exhibit No.
    Description
    99.1
    Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS





    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    Pharming Group N.V.
    By:
    /s/ Fabrice Chouraqui
    Name:
    Fabrice Chouraqui
    Title:
    CEO

    Date: April 23, 2025




















    logo_pharmingxoriginal.jpg
    For media and investors only

    Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

    Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS
    Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)

    Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimbursement and use within the National Health Service (NHS) in England and Wales for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
    The NICE recommendation is based on the totality of the data, including the Phase III clinical trial evaluating leniolisib, an oral selective PI3Kδ inhibitor, in patients with APDS, a rare and progressive primary immunodeficiency. In the primary analysis, treatment with leniolisib led to significant improvements in immune deficiency and immune dysregulation compared to placebo. The Phase III trial demonstrated an improvement in clinical outcomes, which was maintained during longer-term treatment within the open-label extension trial.

    Fabrice Chouraqui, Chief Executive Officer of Pharming, said:
    “This positive recommendation for Joenja® from NICE is a significant milestone for patients living with APDS in England and Wales. It underscores Pharming’s commitment to work closely with regulatory and reimbursement authorities, the medical immunology community, and patient associations to bring this first targeted treatment to patients who may benefit.”

    Professor Sinisa Savic, Professor of Clinical Immunology at St James’s University Hospital, said:
    “Data from clinical trials demonstrate that leniolisib provides real benefits for patients with APDS, a rare primary immunodeficiency. APDS is a complex and progressive condition that leads to immune dysregulation and recurrent infections, significantly impacting patients' quality of life. The recommendation by NICE, which allows this targeted therapy to be prescribed on the NHS, marks an important step forward in improving treatment options for individuals with this condition.”

    Dr Susan Walsh, Chief Executive Officer at Immunodeficiency UK, said:
    “This is a hugely welcomed decision that will make a massive difference to the lives of people with APDS, and their families, by potentially allowing them to have a better quality of life. With leniolisib, we now have a targeted treatment available that addresses the fundamental cause of the immune system problems experienced in APDS. This is a huge leap forward. We are grateful to Pharming for working with NICE to make this drug available via the NHS. Together, they have shown a real commitment to providing people affected by ultra-rare, immune system conditions the treatments they need.”



    logo_pharmingxoriginal.jpg
    The final NICE recommendation aligns with the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) approval and falls under NICE’s Highly Specialised Technologies (HST) pathway, which evaluates treatments for very rare and severe diseases. Leniolisib is now available for use and funded in England through the Innovative Medicines Fund, ensuring immediate patient access. In Wales, leniolisib is expected to be funded within the next three months through the NHS in specialist centers.

    Important Safety Information
    The full Summary of Product Characteristics (SPC/SmPC) for Joenja® (leniolisib) is available on the MHRA website at https://products.mhra.gov.uk/.

    About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS)
    APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation1,2,3 APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide.

    About Joenja® (leniolisib)
    Joenja® (leniolisib) is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved in the U.S., U.K., Australia and Israel as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja® inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and interim open label extension data has supported the safety and tolerability of long-term leniolisib administration.8,9 Leniolisib is currently under regulatory review in the European Economic Area, Canada and several other countries for APDS, with plans to pursue regulatory approval in Japan. Leniolisib is also being evaluated in two Phase III clinical trials in children with APDS and in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS.

    About Pharming Group N.V.
    Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.



    logo_pharmingxoriginal.jpg
    For more information, visit www.pharming.com and find us on LinkedIn.

    Forward-looking Statements
    This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

    Inside Information
    This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

    References
    1.Lucas CL, et al. Nat Immunol. 2014;15(1):88-97. 
    2.Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218. 
    3.Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.  
    4.Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606. 
    5.Maccari ME, et al. Front Immunol. 2018;9:543. 
    6.Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333. 
    7.Condliffe AM, Chandra A. Front Immunol. 2018;9:338. 
    8.Rao VK, et al Blood. 2023 Mar 2;141(9):971-983. 
    9.Rao VK, et al. J Allergy Clin Immunol 2024;153:265-74. 

    For further public information, contact:
    Pharming Group, Leiden, the Netherlands
    Michael Levitan, VP Investor Relations & Corporate Communications
    T: +1 (908) 705 1696
    E: [email protected]


    logo_greyxoriginalx.jpg

    FTI Consulting, London, UK
    Simon Conway/Alex Shaw/Amy Byrne
    T: +44 203 727 1000

    LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
    Leon Melens
    T: +31 6 53 81 64 27
    E: [email protected]

    US PR
    Christina Skrivan
    T: +1 (636) 352-7883
    E: [email protected]

    Get the next $PHAR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAR

    DatePrice TargetRatingAnalyst
    12/9/2024$14.00Buy
    Jefferies
    More analyst ratings

    $PHAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Pharming Group N.V. with a new price target

      Jefferies initiated coverage of Pharming Group N.V. with a rating of Buy and set a new price target of $14.00

      12/9/24 8:05:53 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAR
    SEC Filings

    See more
    • SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

      6-K - Pharming Group N.V. (0001828316) (Filer)

      5/8/25 6:59:48 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

      6-K - Pharming Group N.V. (0001828316) (Filer)

      4/30/25 11:50:45 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

      6-K - Pharming Group N.V. (0001828316) (Filer)

      4/25/25 9:06:32 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAR
    Leadership Updates

    Live Leadership Updates

    See more
    • Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

      Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration pac

      3/4/25 9:15:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

      Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM). Information regarding the EGM, including the notice to convene, will be shared shortly in a separate press release. Upon the appointment of Mr. Chouraqui, Sijmen de Vries will resign from the Board of Directors.

      1/21/25 1:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders

      Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Dr. Richard Peters as Non-Executive director for a period of four years. As a result, Dr. Peters succeeds Mr. Paul Sekhri as Chair of the Board of Directors with immediate effect. Deborah Jorn, Vice-Chair of the Board of Directors, commented: "On behalf of the Board, I would like to thank our outgoing Chairman, Paul Sekhri, for his leadership, over the past eight years. During his tenure as Chairman, Paul a

      9/25/23 10:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pharming Group reports first quarter 2025 financial results and provides business update

      First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product's unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024Launched Joenja® (leniol

      5/8/25 1:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

      Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional primary immunodeficiencies (PIDs) with immune dysregulation. Presentations:Title: Primary and Safety Outcomes of a Phase 3 Open-Label, Single-Arm, 12-Week Study of Treatment With PI3Kδ I

      4/25/25 9:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

      For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimbursement and use within the National Health Service (NHS) in England and Wales for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult

      4/23/25 3:30:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAR
    Financials

    Live finance-specific insights

    See more

    $PHAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Pharming Group reports first quarter 2025 financial results and provides business update

      First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product's unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024Launched Joenja® (leniol

      5/8/25 1:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

      Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45.0 million in the first full year post-launch and fourth quarter revenue increased by 66% to US$13.1 million, compared to the fourth quarter 2023Fourth quarter operating profit increased to US$6.7 million from US$1.1 mil

      3/13/25 2:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharming Group to report fourth quarter and full year 2024 financial results on March 13

      Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025. Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 13, 2025. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call registration:Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register

      2/27/25 2:00:00 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pharming Group N.V. ADS each representing 10

      SC 13G/A - Pharming Group N.V. (0001828316) (Subject)

      11/14/24 6:17:36 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Pharming Group N.V. ADS each representing 10

      SC 13G - Pharming Group N.V. (0001828316) (Subject)

      11/8/24 3:03:47 PM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Pharming Group N.V. ADS each representing 10

      SC 13G - Pharming Group N.V. (0001828316) (Subject)

      2/14/24 7:03:30 AM ET
      $PHAR
      Biotechnology: Pharmaceutical Preparations
      Health Care